Literature DB >> 33760807

SARS-CoV-2 variants reveal features critical for replication in primary human cells.

Marie O Pohl1, Idoia Busnadiego1, Verena Kufner1, Irina Glas1,2, Umut Karakus1, Stefan Schmutz1, Maryam Zaheri1, Irene Abela1, Alexandra Trkola1, Michael Huber1, Silke Stertz1, Benjamin G Hale1.   

Abstract

Since entering the human population, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2; the causative agent of Coronavirus Disease 2019 [COVID-19]) has spread worldwide, causing >100 million infections and >2 million deaths. While large-scale sequencing efforts have identified numerous genetic variants in SARS-CoV-2 during its circulation, it remains largely unclear whether many of these changes impact adaptation, replication, or transmission of the virus. Here, we characterized 14 different low-passage replication-competent human SARS-CoV-2 isolates representing all major European clades observed during the first pandemic wave in early 2020. By integrating viral sequencing data from patient material, virus stocks, and passaging experiments, together with kinetic virus replication data from nonhuman Vero-CCL81 cells and primary differentiated human bronchial epithelial cells (BEpCs), we observed several SARS-CoV-2 features that associate with distinct phenotypes. Notably, naturally occurring variants in Orf3a (Q57H) and nsp2 (T85I) were associated with poor replication in Vero-CCL81 cells but not in BEpCs, while SARS-CoV-2 isolates expressing the Spike D614G variant generally exhibited enhanced replication abilities in BEpCs. Strikingly, low-passage Vero-derived stock preparation of 3 SARS-CoV-2 isolates selected for substitutions at positions 5/6 of E and were highly attenuated in BEpCs, revealing a key cell-specific function to this region. Rare isolate-specific deletions were also observed in the Spike furin cleavage site during Vero-CCL81 passage, but these were rapidly selected against in BEpCs, underscoring the importance of this site for SARS-CoV-2 replication in primary human cells. Overall, our study uncovers sequence features in SARS-CoV-2 variants that determine cell-specific replication and highlights the need to monitor SARS-CoV-2 stocks carefully when phenotyping newly emerging variants or potential variants of concern.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33760807     DOI: 10.1371/journal.pbio.3001006

Source DB:  PubMed          Journal:  PLoS Biol        ISSN: 1544-9173            Impact factor:   8.029


  18 in total

1.  CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva.

Authors:  Enyia R Anderson; Edward I Patterson; Siobhan Richards; Ana K Pitol; Thomas Edwards; Dominic Wooding; Kate Buist; Alison Green; Sayandip Mukherjee; Michael Hoptroff; Grant L Hughes
Journal:  J Med Microbiol       Date:  2022-02       Impact factor: 2.472

2.  Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity.

Authors:  Marie O Pohl; Laura Martin-Sancho; Ranjala Ratnayake; Kris M White; Laura Riva; Qi-Yin Chen; Gauthier Lieber; Idoia Busnadiego; Xin Yin; Samuel Lin; Yuan Pu; Lars Pache; Romel Rosales; Marion Déjosez; Yiren Qin; Paul D De Jesus; Anne Beall; Sunnie Yoh; Benjamin G Hale; Thomas P Zwaka; Naoko Matsunaga; Adolfo García-Sastre; Silke Stertz; Sumit K Chanda; Hendrik Luesch
Journal:  ACS Infect Dis       Date:  2022-06-29       Impact factor: 5.578

3.  Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection.

Authors:  Oluwasanmi O Adenaiye; Jianyu Lai; P Jacob Bueno de Mesquita; Filbert Hong; Somayeh Youssefi; Jennifer German; S H Sheldon Tai; Barbara Albert; Maria Schanz; Stuart Weston; Jun Hang; Christian Fung; Hye Kyung Chung; Kristen K Coleman; Nicolae Sapoval; Todd Treangen; Irina Maljkovic Berry; Kristin Mullins; Matthew Frieman; Tianzhou Ma; Donald K Milton
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

4.  Avoiding culture shock with the SARS-CoV-2 spike protein.

Authors:  Benjamin G Hale
Journal:  Elife       Date:  2021-05-18       Impact factor: 8.140

5.  Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages.

Authors:  Tessa Prince; Xiaofeng Dong; Rebekah Penrice-Randal; Nadine Randle; Catherine Hartley; Hannah Goldswain; Benjamin Jones; Malcolm G Semple; J Kenneth Baillie; Peter J M Openshaw; Lance Turtle; Grant L Hughes; Enyia R Anderson; Edward I Patterson; Julian Druce; Gavin Screaton; Miles W Carroll; James P Stewart; Julian A Hiscox
Journal:  mSphere       Date:  2022-05-02       Impact factor: 5.029

Review 6.  Mechanisms of SARS-CoV-2 entry into cells.

Authors:  Cody B Jackson; Michael Farzan; Bing Chen; Hyeryun Choe
Journal:  Nat Rev Mol Cell Biol       Date:  2021-10-05       Impact factor: 94.444

7.  Manipulation of the unfolded protein response: A pharmacological strategy against coronavirus infection.

Authors:  Liliana Echavarría-Consuegra; Georgia M Cook; Idoia Busnadiego; Charlotte Lefèvre; Sarah Keep; Katherine Brown; Nicole Doyle; Giulia Dowgier; Krzysztof Franaszek; Nathan A Moore; Stuart G Siddell; Erica Bickerton; Benjamin G Hale; Andrew E Firth; Ian Brierley; Nerea Irigoyen
Journal:  PLoS Pathog       Date:  2021-06-17       Impact factor: 6.823

8.  Emerging SARS-CoV-2 Genotypes Show Different Replication Patterns in Human Pulmonary and Intestinal Epithelial Cells.

Authors:  Gabriel Augusto Pires de Souza; Marion Le Bideau; Celine Boschi; Lorène Ferreira; Nathalie Wurtz; Christian Devaux; Philippe Colson; Bernard La Scola
Journal:  Viruses       Date:  2021-12-23       Impact factor: 5.048

9.  Human models for COVID-19 research.

Authors:  Maximillian N J Woodall; Tereza Masonou; Katie-Marie Case; Claire M Smith
Journal:  J Physiol       Date:  2021-08-17       Impact factor: 6.228

10.  SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity.

Authors:  Michihito Sasaki; Shinsuke Toba; Yukari Itakura; Herman M Chambaro; Mai Kishimoto; Koshiro Tabata; Kittiya Intaruck; Kentaro Uemura; Takao Sanaki; Akihiko Sato; William W Hall; Yasuko Orba; Hirofumi Sawa
Journal:  mBio       Date:  2021-08-24       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.